46.25
price up icon1.12%   0.41
 
loading
전일 마감가:
$45.84
열려 있는:
$45.28
하루 거래량:
124.57K
Relative Volume:
0.06
시가총액:
$5.55B
수익:
$692.26M
순이익/손실:
$-512.41M
주가수익비율:
-10.91
EPS:
-4.24
순현금흐름:
$-274.36M
1주 성능:
+3.66%
1개월 성능:
+10.08%
6개월 성능:
+102.60%
1년 성능:
+158.10%
1일 변동 폭
Value
$44.27
$46.45
1주일 범위
Value
$43.50
$47.72
52주 변동 폭
Value
$15.81
$50.89

가든트헬스 Stock (GH) Company Profile

Name
명칭
Guardant Health Inc
Name
전화
855-698-8887
Name
주소
3100 HANOVER STREET, PALO ALTO
Name
직원
0
Name
트위터
@guardanthealth
Name
다음 수익 날짜
2024-11-06
Name
최신 SEC 제출 서류
Name
GH's Discussions on Twitter

GH을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Diagnostics & Research icon
GH
Guardant Health Inc
46.28 5.55B 692.26M -512.41M -274.36M -4.24
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
513.05 196.14B 42.88B 6.34B 7.27B 16.53
Diagnostics & Research icon
DHR
Danaher Corp
210.96 150.10B 23.88B 3.90B 5.30B 5.28
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
419.00 34.06B 3.90B 887.87M 798.08M 10.67
Diagnostics & Research icon
A
Agilent Technologies Inc
119.67 34.07B 6.53B 1.26B 1.31B 4.35
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
179.13 31.53B 15.41B 1.37B 2.11B 7.50

가든트헬스 Stock (GH) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-01-23 개시 Barclays Overweight
2024-06-28 업그레이드 Guggenheim Neutral → Buy
2024-06-03 재개 Jefferies Buy
2024-04-24 재개 Craig Hallum Buy
2023-12-14 개시 Guggenheim Neutral
2023-12-13 개시 Wolfe Research Peer Perform
2023-11-13 업그레이드 Raymond James Mkt Perform → Outperform
2023-09-28 개시 Bernstein Outperform
2023-09-27 업그레이드 Piper Sandler Neutral → Overweight
2023-07-05 재개 JP Morgan Overweight
2023-05-26 업그레이드 Citigroup Neutral → Buy
2023-05-05 개시 UBS Buy
2023-03-09 다운그레이드 Citigroup Buy → Neutral
2023-01-05 개시 Scotiabank Sector Outperform
2022-11-01 다운그레이드 Piper Sandler Overweight → Neutral
2022-10-19 개시 Craig Hallum Buy
2022-10-06 개시 Stephens Overweight
2022-08-25 개시 Credit Suisse Outperform
2022-06-03 개시 Piper Sandler Overweight
2022-04-28 재개 BTIG Research Buy
2022-02-24 재확인 Canaccord Genuity Buy
2022-02-24 재확인 Citigroup Buy
2022-02-24 재확인 Cowen Outperform
2022-02-24 재확인 Morgan Stanley Overweight
2022-02-24 재확인 SVB Leerink Outperform
2022-02-24 재확인 Stifel Buy
2022-02-24 재확인 Wells Fargo Overweight
2021-10-15 재개 Cowen Outperform
2021-06-15 개시 Raymond James Mkt Perform
2021-06-03 개시 Goldman Buy
2021-05-25 개시 Wells Fargo Overweight
2021-01-11 개시 Stifel Buy
2020-09-09 개시 Morgan Stanley Overweight
2020-06-12 개시 BTIG Research Buy
2020-02-21 개시 Guggenheim Buy
2020-01-07 개시 Citigroup Buy
2019-08-07 재확인 Canaccord Genuity Buy
2019-04-16 개시 Canaccord Genuity Buy
2019-04-10 업그레이드 BofA/Merrill Neutral → Buy
2019-02-28 재확인 BofA/Merrill Neutral
2018-10-29 개시 BofA/Merrill Neutral
2018-10-29 개시 JP Morgan Overweight
2018-10-29 개시 William Blair Outperform
모두보기

가든트헬스 주식(GH)의 최신 뉴스

pulisher
Mar 26, 2025

Liquid Biopsy Market Insights and Projections 2025-2032 - openPR

Mar 26, 2025
pulisher
Mar 25, 2025

VA expands coverage to include CRC blood test for veterans - Investing.com India

Mar 25, 2025
pulisher
Mar 25, 2025

Guardant Health shares rise on VA coverage for cancer test - Investing.com

Mar 25, 2025
pulisher
Mar 25, 2025

Guardant Health’s Shield Blood Test Now Covered for VA Community Care Beneficiaries - Yahoo Finance

Mar 25, 2025
pulisher
Mar 25, 2025

Key Market Driver in Breast Cancer Liquid Biopsy Industry 2025: Rising Breast Cancer Cases Fuel Demand For ... - WhaTech

Mar 25, 2025
pulisher
Mar 21, 2025

Guardant Health gains amid $292.5M verdict against Natera over false advertising claims (update) - MSN

Mar 21, 2025
pulisher
Mar 20, 2025

Guardant Health director Tariq Musa sells $5,069 in stock By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Guardant Health director Tariq Musa sells $5,069 in stock - Investing.com India

Mar 20, 2025
pulisher
Mar 18, 2025

AI Healthcare Co. Accuses Test-Maker Of Infringing Patents - Law360

Mar 18, 2025
pulisher
Mar 18, 2025

AI Health Care Co. Accuses Test-Maker Of Infringing Patents - Law360

Mar 18, 2025
pulisher
Mar 18, 2025

Creating awareness for Colorectal Cancer Month - WFLA

Mar 18, 2025
pulisher
Mar 17, 2025

Guardant Accused of Infringing Tempus AI Cancer Research Tech - Bloomberg Law

Mar 17, 2025
pulisher
Mar 14, 2025

Liquid biopsy market flooded with opportunity - BioWorld Online

Mar 14, 2025
pulisher
Mar 14, 2025

Guardant Health rises after Medicare ADLT status for colorectal cancer test - MSN

Mar 14, 2025
pulisher
Mar 13, 2025

Guardant Health: Great Buy On Dips For Strong Diagnostics Verticals Despite Premium Valuation - Seeking Alpha

Mar 13, 2025
pulisher
Mar 12, 2025

Guardant Health at Barclays Conference: Strategic Expansion in Diagnostics By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 12, 2025

Guardant Health’s ADLT Status Boosts Shield CRC Test’s Market Position and Financial Outlook - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

1,415 Shares in Guardant Health, Inc. (NASDAQ:GH) Bought by SBI Securities Co. Ltd. - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Investing in Guardant Health (NASDAQ:GH) a year ago would have delivered you a 129% gain - Simply Wall St

Mar 12, 2025
pulisher
Mar 11, 2025

Raymond James maintains Guardant Health stock at Outperform By Investing.com - Investing.com Canada

Mar 11, 2025
pulisher
Mar 11, 2025

Guardant Health gains ADLT status for CRC blood test By Investing.com - Investing.com Canada

Mar 11, 2025
pulisher
Mar 11, 2025

Guardant Health, Inc. Receives ADLT Status From CMS for Shield Blood Test -March 11, 2025 at 07:00 am EDT - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue - Benzinga

Mar 11, 2025
pulisher
Mar 11, 2025

Sector Update: Health Care -March 11, 2025 at 01:38 pm EDT - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Sector Update: Health Care - TradingView

Mar 11, 2025
pulisher
Mar 11, 2025

Guardant Health stock up on Medicare ADLT status (GH:NASDAQ) - Seeking Alpha

Mar 11, 2025
pulisher
Mar 11, 2025

Guardant Health Shares Soar After Colorectal Cancer Test Granted ADLT Status -March 11, 2025 at 11:01 am EDT - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Citi maintains Buy on Guardant Health, price target at $60 By Investing.com - Investing.com UK

Mar 11, 2025
pulisher
Mar 11, 2025

Guardant Health Receives ADLT Status From CMS for Shield Blood Test - 01Net

Mar 11, 2025
pulisher
Mar 11, 2025

Guardant Health Says Colorectal Cancer Test Granted ADLT Status -March 11, 2025 at 08:48 am EDT - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Guardant Health gains ADLT status for CRC blood test - Investing.com India

Mar 11, 2025
pulisher
Mar 11, 2025

Guardant Health Receives ADLT Status From CMS For Shield Blood Test -March 11, 2025 at 07:19 am EDT - Marketscreener.com

Mar 11, 2025
pulisher
Mar 10, 2025

When the Price of (GH) Talks, People Listen - Stock Traders Daily

Mar 10, 2025
pulisher
Mar 10, 2025

FDA approves blood test for colon cancer detection - MSN

Mar 10, 2025
pulisher
Mar 10, 2025

Bank of New York Mellon Corp Reduces Stock Holdings in Guardant Health, Inc. (NASDAQ:GH) - Defense World

Mar 10, 2025
pulisher
Mar 08, 2025

Morgan Stanley Forecasts Strong Price Appreciation for Guardant Health (NASDAQ:GH) Stock - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Principal Financial Group Inc. Has $308,000 Stake in Guardant Health, Inc. (NASDAQ:GH) - Defense World

Mar 08, 2025
pulisher
Mar 06, 2025

Guardant Health Base Business in 'Fundamentally Good Shape,' Morgan Stanley Says - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Cancer Biomarkers Research Report 2024: Global Market Projected to Soar to USD 62.14 Billion by 2034, Driven by Technological Advancements and Increasing Demand for Early Detection - GlobeNewswire Inc.

Mar 06, 2025
pulisher
Mar 06, 2025

Guardant Health, Inc. (NASDAQ:GH) Short Interest Update - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Lung Cancer Diagnostics Market Growth | Trends, Size & Forecast 2025-2033 | DSS Imagetec, Abbott, Guardant Health. - openPR

Mar 06, 2025
pulisher
Mar 05, 2025

Guardant Health director Joyce sells $4,271 in stock - Investing.com

Mar 05, 2025
pulisher
Mar 05, 2025

Morgan Stanley raises Guardant Health target to $52, maintains Overweight - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

Guardant Health director Joyce sells $4,271 in stock By Investing.com - Investing.com UK

Mar 05, 2025
pulisher
Mar 05, 2025

Guardant Health price target raised to $52 from $42 at Morgan Stanley - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

LSUHS partners with Dak Prescott to boost colon cancer screening - KTALnews.com

Mar 05, 2025
pulisher
Mar 05, 2025

Morgan Stanley raises Guardant Health target to $52, maintains Overweight By Investing.com - Investing.com UK

Mar 05, 2025
pulisher
Mar 05, 2025

Morgan Stanley Adjusts Price Target on Guardant Health to $52 From $42, Keeps Overweight Rating - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Guardant Health at TD Cowen Conference: Strategic Growth and Challenges By Investing.com - Investing.com UK

Mar 05, 2025
pulisher
Mar 05, 2025

Guardant Health Joins Forces With Dak Prescott’s Faith Fight Finish Foundation and Feist-Weiller Cancer Center’s Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities - The Bakersfield Californian

Mar 05, 2025
pulisher
Mar 04, 2025

Commit To Buy Guardant Health At $32, Earn 17.9% Annualized Using Options - Nasdaq

Mar 04, 2025

가든트헬스 (GH) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
diagnostics_research DGX
$167.57
price up icon 0.59%
diagnostics_research LH
$233.69
price up icon 0.15%
$148.50
price down icon 0.92%
diagnostics_research WAT
$370.14
price up icon 0.29%
diagnostics_research MTD
$1,191.15
price up icon 0.18%
diagnostics_research IQV
$179.51
price down icon 0.71%
자본화:     |  볼륨(24시간):